Advertisement

Topics

TNF-Kinoid - Biotech, Pharma and Life Science Channel

11:51 EDT 27th June 2017 | BioPortfolio

Therapies targeting TNF have already demonstrated efficacy across a wide range of inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondulitis, psoriasis and Crohn’s disease. The target market for Kinoids currently in development is estimated at over $24 billion, with potential to reach still broader markets (Source: LaMerie 2012).

Although powerful, current anti-TNFα therapies also have significant drawbacks, making new treatment approaches sorely needed. The most problematic aspect of monoclonal antibody (mAb) therapies is the frequent development of treatment resistance as they are used long-term to treat chronic diseases. For instance in Crohn’s disease, there is loss of response to monoclonal anti-TNF treatment in nearly 60% of patients (infliximab, adalimumab, certolizumab) during the first year of treament. Anti-TNFα treatments also have a cumbersome dosing regimen of frequent IV infusions or SC injections.

The TNF-Kinoid is a promising approach to address the shortcomings of the monoclonal antibodies.

Source: http://www.neovacs.fr/en/products/TNF-Kinoide

News Articles [8 Associated News Articles listed on BioPortfolio]

Neovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 10052017] Prices from USD $250

SummaryNeovacs SA Neovacs is a biotechnology company which develops various therapeutic vaccines for autoimmune disorders, inflammatory diseases and cancers. It offers TNF kinoid and IFNa kinoid produ...

Neovacs to Present Clinical Development Update On IFNα Kinoid in Dermatomyositis

PARIS and BOSTON, May 04, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that Thérèse Cro...

Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks at Upcoming Keystone Symposia Conference:

PARIS and BOSTON, March 09, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that Géraldine Gr...

Neovacs SA ALNEV Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryNeovacs SA Neovacs develops various vaccines. The company offers TNF kinoid and IFNa kinoid products used for the treatment of rheumatoid arthritis, Crohn's disease, cancer; and systemic lupus ...

Neovacs and BioSense Sign Option Agreement Worth Up to €65 Million Plus Royalties for Chinese Development and Commercial Rights to IFNα Kinoid for Lupus and Dermatomyositis

Neovacs receives an upfront fee and is eligible for additional milestone payments and double-digit sales royalties  BioSense receives option for development and commercial rights to IFNα Kinoid f...

Neovacs Issued New Broad Patent in China for IFNα Kinoid

PARIS, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has been granted a n...

Stellar Biotechnologies Congratulates Partner's Decision to Extend Drug Development for Diabetes

LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting ...

Neovacs Announces Independent Data and Safety Monitoring Board Supports Continuation of Phase IIb Clinical Trial for IFNα Kinoid in Lupus

PARIS, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that it received a positive da...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Study of IFN-K in Dermatomyositis

This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis

Study of IFN-K in Systemic Lupus Erythematosus

The safety and immunogenicity of the IFN-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with SLE. Preliminary results were promising. The principal a...

Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists and ADA

The objective of this trial is to demonstrate that active immunization with anti-TNFα kinoid (TNF-K) is able to induce polyclonal anti-TNFα antibodies in RA patients who were previously ...

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attr...

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.

PubMed Articles [0 Results]

None

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topics

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

review and buy TNF-Kinoid market research data and corporate reports here

Channels Quicklinks